Ernexa Therapeutics (ERNAW) Change in Account Payables (2022 - 2026)

Ernexa Therapeutics has reported Change in Account Payables for 4 years, with the latest figure at -$500000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables changed N/A year-over-year to -$500000.0; the trailing twelve-month figure through Mar 2026 stood at -$1.3 million (changed N/A YoY), and the FY2025 full-year result was $750000.0, up 162.24% from the prior year.
• Change in Account Payables for Q1 2026 stood at -$500000.0, up from -$559000.0 in the prior quarter.
• The five-year high for Change in Account Payables was $3.4 million in Q3 2022, with the low at -$559000.0 in Q4 2024.
• Historically, Change in Account Payables has averaged -$45363.6 across 4 years, with a median of -$437000.0 in 2022.
• Annual changes were most pronounced in 2023 — Change in Account Payables plunged 112.91% — and 2024, when it surged 152.05%.
• Ernexa Therapeutics' Change in Account Payables stood at -$437000.0 in 2022, then changed by 0.0% to -$437000.0 in 2023, then retreated by 27.92% to -$559000.0 in 2024, then grew by 10.55% to -$500000.0 in 2026.
• The last three Change in Account Payables figures came in at -$500000.0 (Q1 2026), -$559000.0 (Q4 2024), and $228000.0 (Q3 2024), per Business Quant data.